AstraZeneca Pharma India Limited has fixed July 31, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹36 per equity share for the financial year 2025-26. The dividend, subject to approval by shareholders at the upcoming Annual General Meeting, is scheduled to be paid or dispatched within stipulated timelines. This announcement follows the company's earlier disclosure regarding the dividend recommendation.

For the financial year ended March 31, 2026, the company reported a 33% year-on-year increase in total revenue from operations to ₹22,756 million. This growth was primarily driven by the Oncology business, which surged 44% to reach ₹16,101 million, alongside strong performance in Biopharmaceuticals and Rare Disease therapy areas. The company’s net profit for the year stood at ₹1,875 million.

The Board has recommended the appointment of M/s. BSR & Co. LLP as statutory auditors for a five-year term, replacing M/s. Price Waterhouse and Co. Chartered Accountants LLP, in accordance with mandatory rotation requirements. Additionally, the Board proposed the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director for a second five-year term commencing December 29, 2026.

The 47th Annual General Meeting will be held on August 10, 2026, at 3:00 p.m. IST via Video Conferencing and Other Audio-Visual Means. Remote e-voting facilities will be available from August 6, 2026, at 9:00 a.m. IST until August 9, 2026, at 5:00 p.m. IST. Shareholders holding shares as of the cut-off date of August 3, 2026, are eligible to participate in the voting process. The Board has appointed Mr. Vijayakrishna K.T., Practising Company Secretary, as the Scrutinizer for the e-voting process.

Key AGM Business

Important Dates

AstraZeneca Pharma India Limited has accepted the resignation of Ms. Bhavana Agrawal from the position of Chief Financial Officer (CFO) and Key Managerial Personnel, effective from the close of business hours on August 31, 2026. The resignation follows her appointment to a regional role within the AstraZeneca Group. The company disclosed this development in a filing submitted to the stock exchanges on July 21, 2026.

Regulatory Disclosures

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the necessary details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on behalf of the company.

Resignation Details

Ms. Bhavana Agrawal communicated her resignation to the Board of Directors on July 20, 2026. In her resignation letter, she expressed gratitude to the Board, senior management, and colleagues for their support during her tenure. The specific details regarding the new regional role or the appointment of a successor were not disclosed in the regulatory filing.